Latano-Vision Sine

Latanoprost, the active ingredient in Latano‑Vision Sine, is a prostaglandin analog presented as a topical ophthalmic solution for ocular use. It reduces intraocular pressure by enhancing uveoscleral outflow and is indicated for the management of open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Latano‑Vision Sine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring EU‑quality standards and reliable global distribution. The company provides comprehensive regulatory support and cold‑chain logistics where required for all customers.

Latanoprost is a prostaglandin analog that lowers intraocular pressure in ocular pressure‑related diseases.

Open-angle glaucoma: reduces intraocular pressure to help preserve visual field. Ocular hypertension: lowers intraocular pressure to decrease risk of progression to glaucoma. Pseudoexfoliative glaucoma: decreases pressure to slow optic nerve damage.

Latanoprost may cause ocular and peri‑ocular changes after administration.

Common Side Effects: - Eye redness or hyperemia - Increased eyelash length or density - Darkening of the iris pigment - Eye irritation or foreign‑body sensation - Blurred vision shortly after instillation - Mild ocular discomfort

Serious or Rare Side Effects: - Severe allergic reaction (e.g., swelling, rash) - Uveitis or intraocular inflammation - Macular edema affecting central vision - Paradoxical increase in intraocular pressure - Corneal edema or endothelial dysfunction - Ocular infection secondary to contamination

Before initiating therapy, evaluate ocular health and intraocular pressure baseline.

Baseline assessment: measure intraocular pressure and document iris color. History review: avoid use in patients with active ocular infection or inflammation. Monitoring: schedule regular follow‑up examinations to detect pigmentary changes. Adjunct therapy: consider potential additive effects when combined with other IOP‑lowering agents. Store at below 25°C: keep in the original container, protect from moisture and light, do not freeze.

Latanoprost may interact with other ophthalmic agents, altering efficacy or safety.

Major Interactions (Avoid): - Other prostaglandin analog eye drops: additive IOP‑lowering effect may cause over‑reduction. - Cholinergic agents (e.g., pilocarpine): may diminish latanoprost efficacy.

Moderate Interactions (Monitor Closely): - Topical non‑steroidal anti‑inflammatory drugs: increased risk of ocular irritation. - Beta‑blocker eye drops: potential additive IOP reduction, monitor pressure. - Systemic antihistamines: may exacerbate dry‑eye symptoms. - Carbonic anhydrase inhibitors: monitor for excessive pressure lowering.